Who are CHOP-daclizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chop-daclizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CHOP-daclizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CHOP-daclizumab (CHOP-daclizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (daclizumab component) combined with chemotherapy regimen. Area: Oncology.

marketed Monoclonal antibody (daclizumab component) combined with chemotherapy regimen CD25 (IL-2 receptor alpha chain) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CHOP-daclizumab (CHOP-daclizumab) — King's College Hospital NHS Trust. CHOP-daclizumab is a chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) combined with daclizumab, an anti-CD25 monoclonal antibody that depletes regulatory T cells to enhance immune response against lymphoid malignancies.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CHOP-daclizumab TARGET	CHOP-daclizumab	King's College Hospital NHS Trust	marketed	Monoclonal antibody (daclizumab component) combined with chemotherapy regimen	CD25 (IL-2 receptor alpha chain)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (daclizumab component) combined with chemotherapy regimen class)

King's College Hospital NHS Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHOP-daclizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/chop-daclizumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing